Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 156

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 8
Chunk 156
---
(81)81 — 81 0.05 Adjusted$1,983 $237 $1,746 $1 $1,745 $1.18 

42

Quarterly Results and Business Overview 

The following section describes our net sales and results of operations by reportable segment and business. For additional information on our businesses and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K. 

 Three Months Ended June 30,(in millions)20252024Increase/(Decrease)Endoscopy$737 $676 9.1%Urology676 525 28.9%Neuromodulation303 282 7.2%MedSurg1,716 1,483 15.7%Cardiology2,647 2,047 29.3%Peripheral Interventions698 590 18.3%Cardiovascular3,345 2,637 26.8%Net Sales$5,061 $4,120 22.8%Six Months Ended June 30,(in millions)20252024Increase/(Decrease)Endoscopy$1,410 $1,318 7.0%Urology1,310 1,038 26.2%Neuromodulation574 539 6.5%MedSurg3,293 2,895 13.8%Cardiology5,077 3,919 29.5%Peripheral Interventions1,354 1,163 16.4%Cardiovascular6,430 5,082 26.5%Net Sales$9,724 $7,977 21.9%

MedSurg

Endoscopy 

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions with innovative, less-invasive technologies. Net sales of Endoscopy products of $737 million during the second quarter and $1.410 billion during the first six months of 2025 represented 15 percent and 14 percent of our consolidated net sales, respectively. Endoscopy net sales increased $61 million, or 9.1 percent, during the second quarter and $92 million, or 7.0 percent, during the first six months of 2025, compared to the prior year periods. During the second quarter of 2025, this increase included operational